ATLEY SOLUTIONS, STANFORD AND UC DAVIS DEMONSTRATE PROOF-OF-CONCEPT SUPPLY CHAIN FOR ASTATINE-211 IN CALIFORNIA

Gothenburg, Sweden – 30 May 2026 – Atley Solutions, in collaboration with the Cyclotron & Radiochemistry Facility (CRF) at Stanford University and the Crocker Nuclear Laboratory at UC Davis, today announced the successful demonstration of a proof-of-concept production and logistics workflow for the medical radioisotope astatine-211 (At-211) in California.

The collaboration marks another important step toward scalable and standardized regional access of At-211 for targeted alpha therapies.

The project combines Atley's proprietary target manufacturing and processing know-how with cyclotron infrastructure at the Crocker Nuclear Laboratory at UC Davis and radiochemistry capabilities at the Cyclotron & Radiochemistry Facility (CRF) at Stanford University. The demonstrated workflow included the manufacture and supply of bismuth targets by Atley, target irradiation at UC Davis Crocker Nuclear Laboratory, transport of the irradiated target to Stanford, and purification of At-211 from the irradiated target via dry distillation on an Atley C100 module installed at Stanford University.

This workflow builds on a standardized approach to the At-211 supply chain already demonstrated in Europe, including the shipment of irradiated bismuth material between production and recipient sites, followed by purification on the Atley C100 module for downstream radiochemistry use.

"We are happy to be re-establishing At-211 production at UC Davis, which was originally developed under a grant from the Department of Energy. Parts of the cyclotron at the Crocker Nuclear Laboratory at UC Davis originate from the Berkeley 60-inch Cyclotron used in the discovery of astatine in 1940, and this project links the isotope's scientific origins with its modern development for targeted alpha therapy. This relationship with Atley will allow us to focus on beam performance for production while they handle the preparation and recovery." said Eric Prebys, UC Davis Professor and Director of the Crocker Nuclear Laboratory at UC Davis.

"*We are delighted by the successful demonstration of the At-211 workflow in California, which is an important milestone toward expanding our research and clinical development work with At-211*," said Gunilla Jacobson, PhD, Technical & Strategic Director, CRF, Stanford University.

"*The whole Atley team is excited to be able to support bringing At-211 back to California," said Milton Lönnroth*, CEO of Atley Solutions. "*The successful proof-of-concept shows that our target technology, transport model and Atley C100 purification and synthesis platform can be deployed in a new regional setting. It is a practical step toward building more distributed, reliable and scalable At-211 infrastructure.*"

The collaboration demonstrates how standardized production methods, validated logistics workflows and harmonized target technology can support expansion of a distributed At-211 supply network across institutions and geographies. Following further scale-up, the ambition is for the infrastructure and At-211 supply to become available to multiple radiopharmaceutical companies and researchers.

The work was carried out within the framework of a VINNOVA-funded international collaboration between Atley Solutions, Stanford University and Telix Pharmaceuticals under the 2025 "Deepened collaboration with USA, UK and Singapore within Health and Life Science" program. The aim of the collaboration project is to establish the first operational supply chain for At-211 in California.

About Atley Solutions

Atley Solutions is the global leader in commercial products and services for the development and manufacturing of At-211 radiopharmaceuticals. The Atley C100 is the world's only commercial module for automated manufacturing of At-211 radiopharmaceuticals, addressing key challenges in radionuclide

ATLEY SOLUTIONS

production and supply-chain scalability. In addition to its cutting-edge technology, Atley provides radiopharmaceutical development services and products related to the production of the isotope At-211.

About the Cyclotron & Radiochemistry Facility (CRF) at Stanford University

The CRF is a cGMP radiopharmaceutical manufacturing and research facility within the Department of Radiology at the Stanford University School of Medicine. Its mission is to drive innovation, clinical discoveries, education, and patient care across Stanford-affiliated hospital and clinics. In addition, it supports translation of new radiopharmaceuticals world-wide after initial implementation at Stanford. The CRF fuels discoveries in cancer, neurology, and cardiology, supports investigator-led clinical trials, and anchors major collaborations with industry and federal agencies.

About UC Davis Crocker Nuclear Laboratory

Crocker Nuclear Laboratory at UC Davis is a multidisciplinary facility that provides services and performs research in a variety of areas, including radiations' effects on electronics, proton radiation therapy for ocular cancer, air and chemical analysis, nuclear cross section measurement, and a variety of medical studies.

About Telix Pharmaceuticals

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). For further information visit: www.telixpharma.com

Contact Information

For more information please contact:

Milton Lönnroth

Co-Founder & CEO
Atley Solutions AB
Phone: +46 (0) 704 34 84 57
Email: info@atley.com